Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers

Ipsen And BAKX Will Develop Latter’s BCL-2 Inhibitor

 
• By Sten Stovall
  
Investigational BKX-001 is an oral small-molecule activator of BAX • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D